Bioresorbable Coronary Scaffolds Market Outlook:
Bioresorbable Coronary Scaffolds Market size was valued at USD 876.29 million in 2025 and is projected to reach USD 5.79 billion by the end of 2035, rising at a CAGR of 20.8% during the forecast period, i.e., 2026-2035. In 2026, the industry size of bioresorbable coronary scaffolds is assessed at USD 1.05 billion.
The rising cases of cardiovascular disorder (CVD), particularly conditions such as angina linked to coronary artery disease, are becoming a serious health issue around the world, propelling demand in the bioresorbable coronary scaffolds market. In this regard, the WHO data in July 2025 reported that more than 19.8 million people died of this ailment globally in 2022. Other data published by the Centers for Disease Control and Prevention (CDC) in July 2024 states that the percentage of adults diagnosed with coronary heart disease is 5% in 2024. Additionally, in 2025, Germany was afflicted with peripheral artery disease (PAD), which received treatment with scaffolds. This demography reflects the multi-disciplinary application and sustainable cash inflow for offerings from this sector.
Various factors with economic uncertainty, such as production cost, expenses on material outsourcing, and variability in trade policies, have shown a considerable impact on the payers' pricing structure in the market. Advances in cardiac devices and indications for these devices have occurred during the past decade. These devices are widely used due to their tremendous monitoring and treatment results. Among various advancements, the recent one is the integration of AI for better results in monitoring heart-related problems. For example, in May 2024, Medtronic announced the AI integration into its Reveal Linq ICM devices, which was introduced in Europe by the end of 2024.
